Evidence map›Paper›PMID 39167706›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2024

Presentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE).

Alexandre Duvignaud, Ijeoma C Etafo, Marie Jaspard, Qasim Salau, Béatrice Serra, Abiodun J Kareem, Sylvain Juchet, Tolulope O Jegede, Delphine Gabillard, Abiodun T Abidoye and 21 more

Abstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Clinical Outcomes of Severe Lassa Fever in West Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Alexandre DuvignaudGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.ORCID 0000-0001-7139-2687
Ijeoma C EtafoLassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria.
Marie JaspardGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
Qasim SalauDepartment of Pediatrics, Federal Medical Centre Owo, Owo, Nigeria.
Béatrice SerraGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
Abiodun J KareemDepartment of Pediatrics, Federal Medical Centre Owo, Owo, Nigeria.
Sylvain JuchetGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
Tolulope O JegedeDepartment of Pediatrics, Federal Medical Centre Owo, Owo, Nigeria.
Delphine GabillardGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
Abiodun T AbidoyeLassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria.
Camille Le GalThe Alliance for International Medical Action, Dakar, Senegal.
Chukwuyem AbejegahLassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria.
Sampson OwhinLassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria.
Kevin OkwaraekeThe Alliance for International Medical Action, Dakar, Senegal.
Mahamadou DoutchiThe Alliance for International Medical Action, Dakar, Senegal.
Jackson Katembo VihundiraThe Alliance for International Medical Action, Dakar, Senegal.
Rene-M Besong-LacheThe Alliance for International Medical Action, Dakar, Senegal.
Benjamin SeriProgramme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire.
Marion Bérerd-CamaraThe Alliance for International Medical Action, Dakar, Senegal.
Alex P A SalamNuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Adebola OlayinkaNigeria Centre for Disease Control, Abuja, Nigeria.
Peter HorbyNuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Ephraim Ogbaini-EmovonInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Sophie DuraffourDepartment of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Liasu A AhmedDepartment of Family Medicine, Federal Medical Centre Owo, Owo, Nigeria.
Stephan GüntherDepartment of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Akinola N AdedosuViral Hemorrhagic Fever Laboratory, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria.
Xavier AnglaretGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
Denis MalvyGlobal Health in the Global South Research Team-University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, French Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
Hans J LangThe Alliance for International Medical Action, Dakar, Senegal.
Oladele O AyodejiLassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on the presentation, management, and outcomes of Lassa fever (LF) in children are limited.

methodsDescription of the clinical and biological features, treatment, and outcomes of reverse transcriptase and polymerase chain reaction (RT-PCR)-confirmed LF in children aged under 15, enrolled in the LASsa fever clinical COurse and Prognostic factors in an Epidemic context (LASCOPE) prospective cohort study in Nigeria between April 2018 and February 2023.

resultsOne hundred twenty-four children (aged under 12 months: 19; over 12 months: 105) were hospitalized with RT-PCR-confirmed LF. All received intravenous ribavirin. During follow-up, 99/124 (80%) had fever; 71/124 (57%) had digestive symptoms, vomiting (n = 56/122, 46%) and abdominal pain (n = 34/78 aged ≥5 years, 44%) more often than diarrhea (n = 19/124, 15%); 17/124 (14%) had hemorrhagic signs; 44/112 (39%) had a hematocrit lower than 25%, of whom 32/44 (73%) received transfusions; 44/88 (50%) developed hypotension; 18/112 (16.1%) developed kidney disease improving global outcome (KDIGO) ≥2 acute kidney injury; 10/112 (8.9%) had KDIGO 3 acute kidney failure; 4/124 (3.2%) underwent renal replacement therapy. Seven children died, including 4 aged under 12 months (case fatality rate: under 12 months-22%, 95% confidence interval (CI): 7%-48%; over 12 months-2.9%, 95% CI: 0.7%-8.7%). In univariable analysis, age (P = .003), impaired consciousness (P = .026), and Lassa RT-PCR Ct value (P = .006) were associated with Day 30 mortality.

conclusionsThe fatality rate for children over 12 months hospitalized with LF was lower than that previously reported for adults. Hypotension and acute kidney injury were the most frequent organ dysfunctions. Bleeding was relatively infrequent. Anemia and the need for transfusion were common, the relative contribution of ribavirin-induced hemolysis being unknown.

Indexed as

Antiviral AgentsLassa FeverRibavirinAcute Kidney InjuryAdolescentChildChild, PreschoolFemaleHospitalizationHumansInfantLassa virusMaleNigeriaProspective StudiesAntiviral AgentsRibavirinacute kidney injuryanemiachildrenLassa feverNigeriaprognosis

Identifiers

PMID39167706
PMCPMC11631139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.